Cart
sales@molnova.com
WJ460
CAS No. 1415251-36-3
WJ460( —— )
Catalog No. M26864 CAS No. 1415251-36-3
WJ460 is an effective inhibitor of myoferlin. WJ460 exerts anti-metastatic activity in breast cancer cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 83 | In Stock |
|
| 5MG | 82 | In Stock |
|
| 10MG | 139 | In Stock |
|
| 25MG | 226 | In Stock |
|
| 50MG | 333 | In Stock |
|
| 100MG | 485 | In Stock |
|
| 200MG | 668 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWJ460
-
NoteResearch use only, not for human use.
-
Brief DescriptionWJ460 is an effective inhibitor of myoferlin. WJ460 exerts anti-metastatic activity in breast cancer cells.
-
DescriptionWJ460 is an effective inhibitor of myoferlin. WJ460 exerts anti-metastatic activity in breast cancer cells.(In Vitro):WJ460 dose-dependently blocks breast cancer cell invasion through Collagen I(IC50: 43.37 nM in MDA-MB-231 and 36.40 nM in BT549 cells).(In Vivo):In a spontaneous metastasis model, WJ460 inhibits angiogenesis, breast tumor growth, and spontaneous metastasis .
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAdrenocorticotropic hormone (ACTH)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1415251-36-3
-
Formula Weight460.59
-
Molecular FormulaC27H28N2O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NCCCCC=1C=CC=CC1)C2=CC=CC(=C2)C3SCC(=O)N3C=4C=CC=CC4OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Francesco Iuliano, et al. Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation.
molnova catalog
related products
-
Lin281632
Lin281632 is an inhibitor of RNA binding protein Lin28 and bromodomain. Lin281632 promotes mESC differentiation.
-
R 715
R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin -diabetic mice.
-
BC-1382
BC-1382 is a potent ubiquitin E3 ligase HECTD2 inhibitor that specificly disrupts the HECTD2/PIAS1 interaction(IC50 of 5 nM).BC-1382, that targeted HECTD2 and attenuated lipopolysaccharide (LPS)- and Pseudomonas aeruginosa-induced lung inflammation.?
